aray-8k_20201029.htm
false 0001138723 0001138723 2020-10-29 2020-10-29

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 29, 2020

 

 

ACCURAY INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-33301

 

20-8370041

(Commission File Number)

 

(IRS Employer Identification No.)

 

1310 Chesapeake Terrace
Sunnyvale, California 94089

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (408) 716-4600

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

 

ARAY

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 2.02. Results of Operations and Financial Condition.

 

On October 29, 2020, Accuray Incorporated (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended September 30, 2020. A copy of the Company’s press release dated October 29, 2020, titled “Accuray Reports Fiscal 2021 First Quarter Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

 

Exhibit No.

 

Description

99.1

 

Press release dated October 29, 2020, titled “Accuray Reports Fiscal 2021 First Quarter Financial Results”

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ACCURAY INCORPORATED

 

 

 

Dated: October 29, 2020

By:

/s/ Shig Hamamatsu

 

 

Shig Hamamatsu

 

 

Senior Vice President & Chief Financial Officer

 

3

aray-ex991_6.htm

Exhibit 99.1

 

 

 

Joe Diaz

Beth Kaplan

Investor Relations, Lytham Partners

Public Relations Director, Accuray

+1 (602) 889-9700

+1 (408) 789-4426

diaz@lythampartners.com

bkaplan@accuray.com

 

Accuray Reports First Quarter Fiscal 2021 Financial Results

 

SUNNYVALE, Calif., October 29, 2020 — Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2021 ended September 30, 2020.

 

First Quarter Fiscal 2021 Summary

 

 

Net revenue of $85.3 million, operating income of $5.5 million

 

Adjusted EBITDA grew to $9 million from a loss of $1 million in the prior year first quarter

 

Gross orders of $50.5 million, ending backlog of $597.3 million, an increase of 21 percent from September 30, 2019

 

Other Recent Operational Highlights

 

 

Expect revenue recognition for China Type A systems previously awarded in October 2019 to start in the second quarter of fiscal 2021

 

Introduced ClearRT™ Helical kVCT Imaging for the Radixact System at ASTRO 2020

 

44 clinical abstracts related to customer clinical experience on CyberKnife and TomoTherapy/Radixact exhibited at ASTRO 2020 Scientific Sessions

 

“We are off to a solid start in fiscal 2021 despite the headwinds created by the COVID-19 environment. Our global team continues to adapt and make the necessary adjustments to compete and operate effectively given the current market conditions and delivered the fourth consecutive quarter of operating profit, said Joshua H. Levine, President and CEO of Accuray. “Looking ahead, we will be focused on driving the revenue conversion process related to the China Type A systems beginning in the second quarter. Concurrent with this year’s recent ASTRO meeting, we have received very positive customer feedback related to the introduction of our ClearRT™ Helical kVCT imaging upgrade for the Radixact System as we drive our long-term strategic commitment to continued innovation.”

 

Q1 Fiscal 2021 Financial Highlights

Gross product orders totaled $50.5 million for the first quarter of fiscal 2021 compared to $78.5 million for the prior fiscal year first quarter. Order backlog as of September 30, 2020 was $597.3 million, approximately 21 percent higher than at the end of the prior fiscal year first quarter.

Total net revenue was $85.3 million for the first quarter of fiscal 2021 compared to $89.6 million for the prior fiscal year first quarter. Product revenue totaled $31.3 million for the first quarter of fiscal 2021 compared to $37.6 million for the prior fiscal year first quarter, while service revenue totaled $54.1 million for the first quarter of fiscal 2021 compared to $52.0 million for the prior fiscal year first quarter.

Total gross profit for the first quarter of fiscal 2021 was $35.4 million or approximately 41.5 percent of total net revenue, comprised of product gross margin of 41.1 percent of product net revenue and service gross margin of 41.7 percent of service net revenue. This compares to total gross profit of $32.9 million or 36.8 percent of total net revenue, comprised of product gross margin of 42.6 percent of product net revenue and service gross margin of 32.5 percent of service net revenue for the prior fiscal year first quarter.


Net income was $0.4 million, or $0.0 per share, for the first quarter of fiscal 2021, compared to a net loss of $9.4 million,


or a loss of $0.11 per share, for the prior fiscal year first quarter.

Adjusted EBITDA for the first quarter of fiscal 2021 was a positive $9.0 million, compared to a negative $1.0 million for the prior fiscal year first quarter.

Cash, cash equivalents, and short-term restricted cash were $95.5 million as of September 30, 2020, a decrease of $13.1 million from June 30, 2020 primarily due to a $10 million prepayment in principal with respect to our long-term debt.

 

Financial Guidance

The impact of the COVID-19 pandemic on Accuray’s fiscal 2021 results remains uncertain. Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to refrain from providing financial guidance for fiscal year 2021.

 

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2021 as well as recent corporate developments. Conference call dial-in information is as follows:

 

U.S. callers: (877) 270-2148

 

International callers: (412) 902-6510


Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray’s website, www.accuray.com.

 

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion and available for seven days. The replay telephone number is (877) 344-7529 (USA) or (412) 317-0088 (International), Conference ID:10148905. An archived webcast will also be available at Accuray’s website until Accuray announces its results for the second quarter of fiscal 2021.

Use of Non-GAAP Financial Measures

 

Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation (“adjusted EBITDA”). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

 

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.

 

About Accuray

 

Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com.

 

Safe Harbor Statement

 


Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations; expectations regarding the effect of the COVID-19 pandemic on the company and the company’s position in a post-COVID-19 environment; the company’s ability to adapt and make the necessary adjustments to compete and operate effectively; the company’s ability to realize the benefits of working capital management and cash preservation activities; expectations regarding future sales in China; expectations regarding the company’s Chinese joint venture, including the timing of revenue conversion and the manufacture and shipment of a joint venture manufactured product; expectations regarding the company’s product portfolio, including with respect to the company’s Synchrony and Clear RT Helical kVCT imaging upgrades as well as other strategic product innovations; expectations regarding the new Centers for Medicare and Medicaid Services alternative payment model and reimbursement schedule; expectations regarding gross orders, revenue and product mix; expectations regarding the future of radiotherapy treatment; and the company's leadership position in radiation oncology innovation and technologies.  These forward-looking statements involve risks and uncertainties.  If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company’s ability to develop new products or enhance existing products to meet customers’ needs and compete favorably in the market, the company’s ability to effectively integrate and execute the joint venture, the company’s ability to realize the expected benefits of the joint venture; the ability of customers in China to obtain Class A or B user licenses to purchase radiotherapy systems; risks inherent in international operations; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020 and as updated periodically with the company's other filings with the SEC.

 

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events.  The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

 

 

###

 

Financial Tables to Follow

 

 


 Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

 

2020

 

 

2019

 

Gross Orders

 

$

50,528

 

 

$

78,487

 

Net Orders

 

 

23,554

 

 

 

38,981

 

Order Backlog

 

 

597,276

 

 

 

495,029

 

Net revenue:

 

 

 

 

 

 

 

 

Products

 

$

31,258

 

 

$

37,605

 

Services

 

 

54,074

 

 

 

51,972

 

Total net revenue

 

 

85,332

 

 

 

89,577

 

Cost of revenue:

 

 

 

 

 

 

 

 

Cost of products

 

 

18,426

 

 

 

21,570

 

Cost of services

 

 

31,503

 

 

 

35,064

 

Total cost of revenue

 

 

49,929

 

 

 

56,634

 

Gross profit

 

 

35,403

 

 

 

32,943

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

12,148

 

 

 

13,341

 

Selling and marketing

 

 

8,898

 

 

 

13,266

 

General and administrative

 

 

8,889

 

 

 

10,616

 

Total operating expenses

 

 

29,935

 

 

 

37,223

 

Income (loss) from operations

 

 

5,468

 

 

 

(4,280

)

Loss on equity investment, net

 

 

(28

)

 

 

 

Other expense, net

 

 

(4,694

)

 

 

(4,439

)

Income (loss) before provision for income taxes

 

 

746

 

 

 

(8,719

)

Provision for income taxes

 

 

344

 

 

 

637

 

Net income (loss)

 

$

402

 

 

$

(9,356

)

Net income (loss) per share - basic

 

$

0.00

 

 

$

(0.11

)

Net income (loss) per share - diluted

 

$

0.00

 

 

$

(0.11

)

Weighted average common shares used in

   computing income (loss) per share:

 

 

 

 

 

 

 

 

Basic

 

 

91,194

 

 

 

88,772

 

Diluted

 

 

91,681

 

 

 

88,772

 

 

 

 


Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)

 

 

 

 

September 30,

 

 

June 30,

 

 

 

2020

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

89,955

 

 

$

107,577

 

Restricted cash

 

 

5,531

 

 

 

997

 

Accounts receivable, net

 

 

75,034

 

 

 

90,599

 

Inventories, net

 

 

141,017

 

 

 

134,374

 

Prepaid expenses and other current assets

 

 

18,139

 

 

 

21,227

 

Deferred cost of revenue

 

 

2,800

 

 

 

2,712

 

Total current assets

 

 

332,476

 

 

 

357,486

 

Property and equipment, net

 

 

14,540

 

 

 

15,349

 

Investment in joint venture

 

 

15,591

 

 

 

13,929

 

Goodwill

 

 

57,834

 

 

 

57,717

 

Intangible assets, net

 

 

606

 

 

 

663

 

Operating lease right-of-use assets

 

 

27,377

 

 

 

28,647

 

Other assets

 

 

16,286

 

 

 

17,136

 

Total assets

 

$

464,710

 

 

$

490,927

 

Liabilities and equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Short-term debt

 

$

6,162

 

 

$

 

Accounts payable

 

 

17,841

 

 

 

23,126

 

Accrued compensation

 

 

19,618

 

 

 

17,963

 

Operating lease liabilities, current

 

 

8,381

 

 

 

8,224

 

Other accrued liabilities

 

 

19,047

 

 

 

27,180

 

Customer advances

 

 

16,712

 

 

 

22,571

 

Deferred revenue

 

 

81,344

 

 

 

83,207

 

Total current liabilities

 

 

169,105

 

 

 

182,271

 

Long-term other liabilities

 

 

7,644

 

 

 

7,416

 

Deferred revenue

 

 

24,406

 

 

 

24,125

 

Operating lease liabilities, non-current

 

 

22,588

 

 

 

24,173

 

Long-term debt

 

 

173,527

 

 

 

189,307

 

Total liabilities

 

 

397,270

 

 

 

427,292

 

Equity:

 

 

 

 

 

 

 

 

Common stock

 

 

91

 

 

 

91

 

Additional paid-in capital

 

 

547,651

 

 

 

545,741

 

Accumulated other comprehensive income (loss)

 

 

1,009

 

 

 

(484

)

Accumulated deficit

 

 

(481,311

)

 

 

(481,713

)

Total equity

 

 

67,440

 

 

 

63,635

 

Total liabilities and equity

 

$

464,710

 

 

$

490,927

 

 


Accuray Incorporated

Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)

 

 

 

 

Three Months Ended

September 30,

 

 

 

2020

 

 

2019

 

GAAP net income (loss)

 

$

402

 

 

$

(9,356

)

Depreciation and amortization

 

 

1,650

 

 

 

1,851

 

Stock-based compensation

 

 

2,244

 

 

 

1,700

 

Interest expense, net

 

 

4,393

 

 

 

4,200

 

Provision for income taxes

 

 

344

 

 

 

637

 

Adjusted EBITDA

 

$

9,033

 

 

$

(968

)